Skip to main content
OpenTrials
Completed

NCT Number: NCT01666041

Vascular and Metabolic Effects of Fenofibrate/Omega vs Fenofibrate

The investigators hypothesize that fenofibrate/omega will improve insulin resistance compared with fenofibrate

Completed

Looking for future studies?

Notify Me

Key information

Age range

25 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Gil Medical Center

Incheon, 405-760, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • hypertriglyceridemia

Exclusion criteria

  • moderate or severe hypertension, uncontrolled diabetes (HbA1c > 9%), nephrotic syndrome, hypothyroidism, coronary artery disease, or peripheral vascular disease

Treatment and study plan

Placebo

Drug

fenofibrate/omega

Drug

fenofibrate

Drug

Primary outcomes

  1. flow-mediated dilation

    Time frame: 8 weeks of treatment

Secondary outcomes

  1. insulin resistance

    Time frame: 8 weeks of treatment

Sponsors and collaborators

Lead sponsor

Gachon University Gil Medical Center

Other

Registry information

Important dates

Study start
2012
Primary completion
2013
Study completion
2013
First posted
Aug 16, 2012
Registry last updated
Nov 4, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.